ID   HL60-CDR
AC   CVCL_C1LK
DR   cancercelllines; CVCL_C1LK
DR   Wikidata; Q114311625
RX   PubMed=35822500;
CC   Population: Caucasian.
CC   Characteristics: Resistant to doxorubicin, cisplatin, etoposide and daunorubicin (PubMed=35822500).
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0002 ! HL-60
SX   Female
AG   36Y
CA   Cancer cell line
DT   Created: 22-09-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=35822500; DOI=10.1080/1120009X.2022.2097432;
RA   Castro I., Lopes-Rodrigues V., Branco H., Vasconcelos M.H.,
RA   Xavier C.P.R.;
RT   "Establishing and characterizing a novel doxorubicin-resistant acute
RT   myeloid leukaemia cell line.";
RL   J. Chemother. 35:307-321(2023).
//